ESPREsperion Therapeutics, Inc.

$519M

Q2 2021 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$41M-80.8% YoY

Gross Profit

$39M95.6% margin

Operating Income

-$33M-80.0% margin

Net Income

-$44M-107.4% margin

EPS (Diluted)

$-1.67

QoQ Revenue Growth

+409.6%

Cash Flow

Operating Cash Flow

-$48M

Free Cash Flow

-$48M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$280M

Total Liabilities

$585M

Stockholders' Equity

-$304M

Cash & Equivalents

$219M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$41M	$212M	-80.8%
Gross Profit	$39M	$212M	-81.7%
Operating Income	-$33M	$129M	-125.2%
Net Income	-$44M	$125M	-135.0%

Revenue Segments

Collaboration Revenue

$30M94%

Royalty Revenue And Product Sales Bulk Tablets Nilemdo And Nustendi

$2M6%

ESPR Q2 2021 Earnings — Esperion Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena